Literature DB >> 12764268

The impact of patient age and aortic size on the results of aortobifemoral bypass grafting.

Amy B Reed1, Michael S Conte, Magruder C Donaldson, John A Mannick, Anthony D Whittemore, Michael Belkin.   

Abstract

OBJECTIVES: On the basis of the widespread belief that aortobifemoral bypass (ABF) represents the optimal mode of revascularization for patients with diffuse aortoiliac disease, vascular surgeons are often aggressive about its application in young adults. We undertook this retrospective evaluation of ABFs performed from 1980 to 1999 to determine whether the results justify this approach. Patients of less than 50 years of age (n = 45) were compared with those aged 50 to 59 years (n = 93) and those aged more than 60 years (n = 146).
RESULTS: Younger patients were more likely to undergo operation for claudication than were older patients (72% versus 59% and 55%; P <.04). Younger patients were significantly more likely to be smokers (87%) but less likely to have diabetes, hypertension, or cerebrovascular disease. Bypasses were constructed in an end-to-end fashion in 71.1% of patients of less than 50 years versus 68.8% and 71.2% of older patients (P = not significant). The mean diameter of aortic grafts was significantly smaller in younger patients (14.6 mm) than in older patients (15.6 mm and 15.5 mm; P <.01). The need for a subsequent infrainguinal reconstruction was highest in the youngest patients (24% versus 17% and 7%; P <.01). Surgical mortality rates were low in all groups (0%, 1%, and 2.0% for increasing age groups; P = not significant). Five-year primary and secondary patency rates increased significantly with each increase in age interval: 5-year primary patency rate: less than 50 years, 66% +/- 8%; 50 to 59 years, 87% +/- 5%; more than 60 years, 96% +/-2% (P <.05 for all comparisons). Five-year secondary patency rates were: less than 50 years, 79% +/- 7%; 50 to 59 years, 91% +/- 4%; more than 60 years, 98% +/- 2% (P <.05 for all comparisons). Five-year survival rate was comparable in all three groups: less than 50 years, 93% +/- 5%; 50 to 59 years, 92% +/- 4%; more than 60 years, 87% +/- 4% (P = not significant).
CONCLUSION: Increased virulence of aortic disease, smaller aortic size, and more progressive infrainguinal disease may all negatively impact the results of ABF in younger patients. Although 5-year results are acceptable, increased caution is warranted in the routine application of ABF in young patients without limb-threatening ischemia.

Entities:  

Mesh:

Year:  2003        PMID: 12764268     DOI: 10.1016/s0741-5214(02)75179-3

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

Review 1.  Strategies for managing aortoiliac occlusions: access, treatment and outcomes.

Authors:  Daniel G Clair; Jocelyn M Beach
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-05

2.  Lowered LDL-C Levels Reduce Later Local Vascular Events after Surgical or Endovascular Treatment of Peripheral Artery Disease.

Authors:  Kouji Ishii; Junichiro Takahashi; Tsuyoshi Kanaoka; Yutaka Wakamatsu; Toshihiro Gohda; Shigeyuki Sasaki; Yoshiro Matsui
Journal:  Ann Vasc Dis       Date:  2012

3.  Extra-anatomical bypass grafting--a single surgeon's experience.

Authors:  N D Appleton; D Bosanquet; G Morris-Stiff; H Ahmed; P Sanjay; M H Lewis
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

4.  DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents in the common iliac artery: study protocol for a randomized controlled trial.

Authors:  Joost A Bekken; Jan Albert Vos; Ruud A Aarts; Jean-Paul P M de Vries; Bram Fioole
Journal:  Trials       Date:  2012-11-19       Impact factor: 2.279

5.  Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease.

Authors:  Sandra Spronk; Johanna L Bosch; Constance Ryjewski; Judith Rosenblum; Guido C Kaandorp; John V White; M G Myriam Hunink
Journal:  PLoS One       Date:  2008-12-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.